JP2020504139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504139A5 JP2020504139A5 JP2019537063A JP2019537063A JP2020504139A5 JP 2020504139 A5 JP2020504139 A5 JP 2020504139A5 JP 2019537063 A JP2019537063 A JP 2019537063A JP 2019537063 A JP2019537063 A JP 2019537063A JP 2020504139 A5 JP2020504139 A5 JP 2020504139A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- quinoxaline
- triazolo
- dimethyl
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 ethylenedioxy group Chemical group 0.000 claims description 203
- 229910052757 nitrogen Inorganic materials 0.000 claims description 159
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 claims description 150
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 96
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 49
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 42
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 15
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims description 4
- JSQCGWYNOZMHJE-UHFFFAOYSA-N 1-[2-chloro-4-(1-piperidin-1-yl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl)phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1CCCCC1)Cl)C JSQCGWYNOZMHJE-UHFFFAOYSA-N 0.000 claims description 3
- AWBDUOMWRGDOKR-KDURUIRLSA-N 1-[2-chloro-6-(trifluoromethyl)-4-[1-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1C(F)(F)F)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)Cl)C AWBDUOMWRGDOKR-KDURUIRLSA-N 0.000 claims description 3
- HBRKAOFGYWODRB-KDURUIRLSA-N 1-[2-fluoro-6-(trifluoromethyl)-4-[1-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1C(F)(F)F)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)F)C HBRKAOFGYWODRB-KDURUIRLSA-N 0.000 claims description 3
- NQNYGHMIJGDQDL-HDICACEKSA-N 3-[2-chloro-6-(trifluoromethyl)-4-[1-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenoxy]-N,N-dimethylpropan-1-amine Chemical compound ClC1=C(OCCCN(C)C)C(=CC(=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F NQNYGHMIJGDQDL-HDICACEKSA-N 0.000 claims description 3
- DIXUBLFTHVMWLR-HDICACEKSA-N 3-[2-fluoro-6-(trifluoromethyl)-4-[1-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenoxy]-N,N-dimethylpropan-1-amine Chemical compound FC1=C(OCCCN(C)C)C(=CC(=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F DIXUBLFTHVMWLR-HDICACEKSA-N 0.000 claims description 3
- RABLNLIHIGOBNY-KDURUIRLSA-N 3-[4-[1-[(3R,5S)-3,5-dimethylpiperidin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-2-(trifluoromethyl)phenoxy]-N,N-dimethylpropan-1-amine Chemical compound CN(CCCOC1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](C[C@@H](C1)C)C)C(F)(F)F)C RABLNLIHIGOBNY-KDURUIRLSA-N 0.000 claims description 3
- JHUPAEUBHORZLR-BGYRXZFFSA-N N,N-dimethyl-1-[2-(trifluoromethyl)-4-[1-[(3S,5R)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenyl]piperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F)C JHUPAEUBHORZLR-BGYRXZFFSA-N 0.000 claims description 3
- IZOHQVJQWJYVRY-KDURUIRLSA-N N,N-dimethyl-3-[2-(trifluoromethyl)-4-[1-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenoxy]propan-1-amine Chemical compound CN(CCCOC1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F)C IZOHQVJQWJYVRY-KDURUIRLSA-N 0.000 claims description 3
- REBUNDZNCXGPSB-UHFFFAOYSA-N N,N-dimethyl-3-[4-(1-piperidin-1-yl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl)phenoxy]propan-1-amine Chemical compound CN(CCCOC1=CC=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1CCCCC1)C REBUNDZNCXGPSB-UHFFFAOYSA-N 0.000 claims description 3
- FQXBWQABGBJRSC-UHFFFAOYSA-N N,N-dimethyl-3-[4-[1-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenoxy]propan-1-amine Chemical compound CN(C)CCCOC1=CC=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1CCN(CC1)C FQXBWQABGBJRSC-UHFFFAOYSA-N 0.000 claims description 3
- QHHINYLYLKQVHH-BGYRXZFFSA-N N-ethyl-1-[2-(trifluoromethyl)-4-[1-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenyl]piperidin-4-amine Chemical compound C(C)NC1CCN(CC1)C1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F QHHINYLYLKQVHH-BGYRXZFFSA-N 0.000 claims description 3
- DGWGSNCNMUVWDC-KDURUIRLSA-N N-methyl-1-[2-(trifluoromethyl)-4-[1-[(3S,5R)-3,4,5-trimethylpiperazin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]phenyl]piperidin-4-amine Chemical compound CNC1CCN(CC1)C1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F DGWGSNCNMUVWDC-KDURUIRLSA-N 0.000 claims description 3
- PYSRDFNFIZKLFZ-UHFFFAOYSA-N 1-[2-fluoro-4-(1-piperidin-1-yl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl)phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1CCCCC1)F)C PYSRDFNFIZKLFZ-UHFFFAOYSA-N 0.000 claims description 2
- PTYSLACARNYDSH-BGYRXZFFSA-N 1-[4-[1-[(3S,5R)-3,5-dimethylpiperidin-1-yl]-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-2-(trifluoromethyl)phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1)C1=CC=C2N=CC=3N(C2=C1)C(=NN=3)N1C[C@@H](C[C@@H](C1)C)C)C(F)(F)F)C PTYSLACARNYDSH-BGYRXZFFSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000003277 amino group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 8
- 108010016076 Octreotide Proteins 0.000 claims 8
- 229960002700 octreotide Drugs 0.000 claims 8
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 7
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 7
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 7
- 229960001467 bortezomib Drugs 0.000 claims 7
- 229960002448 dasatinib Drugs 0.000 claims 7
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims 6
- 229960003539 mitoguazone Drugs 0.000 claims 6
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 6
- 229960001346 nilotinib Drugs 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 6
- 229960004528 vincristine Drugs 0.000 claims 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 5
- 125000004423 acyloxy group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229960004397 cyclophosphamide Drugs 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 4
- 229960000684 cytarabine Drugs 0.000 claims 4
- 229960002584 gefitinib Drugs 0.000 claims 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 108010006654 Bleomycin Proteins 0.000 claims 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 3
- QNSRYVDGWDXBHV-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]quinoxaline Chemical group C1=CC=C2N3C=NN=C3C=NC2=C1 QNSRYVDGWDXBHV-UHFFFAOYSA-N 0.000 claims 3
- 125000003368 amide group Chemical group 0.000 claims 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 3
- 229960002707 bendamustine Drugs 0.000 claims 3
- 150000001555 benzenes Chemical group 0.000 claims 3
- 229960001561 bleomycin Drugs 0.000 claims 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 3
- 229960001101 ifosfamide Drugs 0.000 claims 3
- 229960004891 lapatinib Drugs 0.000 claims 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 229960004857 mitomycin Drugs 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 150000003216 pyrazines Chemical group 0.000 claims 3
- 150000003230 pyrimidines Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 229960004964 temozolomide Drugs 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 2
- 229960004176 aclarubicin Drugs 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 229960005310 aldesleukin Drugs 0.000 claims 2
- 108700025316 aldesleukin Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- IAKHMKGGTNLKSZ-UHFFFAOYSA-N colchicine Chemical compound C1CC(NC(C)=O)C2=CC(=O)C(OC)=CC=C2C2=C1C=C(OC)C(OC)=C2OC IAKHMKGGTNLKSZ-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229960001251 denosumab Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 229940022353 herceptin Drugs 0.000 claims 2
- 229960001330 hydroxycarbamide Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- 229960001156 mitoxantrone Drugs 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims 2
- 229960000801 nelarabine Drugs 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 229960000572 olaparib Drugs 0.000 claims 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 2
- 229960004390 palbociclib Drugs 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- 229950004550 talazoparib Drugs 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 229940021747 therapeutic vaccine Drugs 0.000 claims 2
- 229960003087 tioguanine Drugs 0.000 claims 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 229960004276 zoledronic acid Drugs 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 3
- YESGQYRYYGXEAP-HDICACEKSA-N 1-[2-fluoro-4-[3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenyl]-N-methylpiperidin-4-amine Chemical compound CNC1CCN(CC1)C1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)F YESGQYRYYGXEAP-HDICACEKSA-N 0.000 description 2
- DGMIZJDKQMRKPX-OYRHEFFESA-N 1-[4-[3-[(3R,5S)-3,5-dimethyl-4-propan-2-ylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]-2-(trifluoromethyl)phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C(C)C)C)C(F)(F)F)C DGMIZJDKQMRKPX-OYRHEFFESA-N 0.000 description 2
- GJHIHENXWOTKPM-KDURUIRLSA-N 1-[4-[3-[(3S,5R)-3,5-dimethylpiperidin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]-2-(trifluoromethyl)phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](C[C@@H](C1)C)C)C(F)(F)F)C GJHIHENXWOTKPM-KDURUIRLSA-N 0.000 description 2
- WPSSPNPUMXQDTH-BGYRXZFFSA-N 1-[4-[3-[(3S,5R)-4-ethyl-3,5-dimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]-2-(trifluoromethyl)phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)CC)C)C(F)(F)F)C WPSSPNPUMXQDTH-BGYRXZFFSA-N 0.000 description 2
- IODXDZKTVIWACE-UHFFFAOYSA-N 1-[4-[3-[4-(dimethylamino)piperidin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]-2-(trifluoromethyl)phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=NN=C2N1C1=C(N=C2)C=CC(=N1)C1=CC(=C(C=C1)N1CCC(CC1)N(C)C)C(F)(F)F)C IODXDZKTVIWACE-UHFFFAOYSA-N 0.000 description 2
- MKEPJDOADBVVQR-UHFFFAOYSA-N 1-[4-[3-[4-(dimethylamino)piperidin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]-2-fluorophenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=NN=C2N1C1=C(N=C2)C=CC(=N1)C1=CC(=C(C=C1)N1CCC(CC1)N(C)C)F)C MKEPJDOADBVVQR-UHFFFAOYSA-N 0.000 description 2
- AECBCBVDJJXNRO-UHFFFAOYSA-N 1-[4-[3-[4-(dimethylamino)piperidin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenyl]-N,N-dimethylpiperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=NN=C2N1C1=C(N=C2)C=CC(=N1)C1=CC=C(C=C1)N1CCC(CC1)N(C)C)C AECBCBVDJJXNRO-UHFFFAOYSA-N 0.000 description 2
- MERPVVCWKJFKCK-HDICACEKSA-N 3-[2-chloro-4-[3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenoxy]-N,N-dimethylpropan-1-amine Chemical compound CN(CCCOC1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)Cl)C MERPVVCWKJFKCK-HDICACEKSA-N 0.000 description 2
- VGFQFMYJYDABME-HDICACEKSA-N 3-[2-fluoro-4-[3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenoxy]-N,N-dimethylpropan-1-amine Chemical compound CN(CCCOC1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)F)C VGFQFMYJYDABME-HDICACEKSA-N 0.000 description 2
- GUYRAPIUJSNWTF-HDICACEKSA-N 3-[4-[3-[(3S,5R)-3,5-dimethylpiperidin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]-2-(trifluoromethyl)phenoxy]-N,N-dimethylpropan-1-amine Chemical compound CN(CCCOC1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](C[C@@H](C1)C)C)C(F)(F)F)C GUYRAPIUJSNWTF-HDICACEKSA-N 0.000 description 2
- MKFOYWITVVTFOH-UHFFFAOYSA-N C1=CN=CC2=C1N3C=NN=C3C=N2 Chemical compound C1=CN=CC2=C1N3C=NN=C3C=N2 MKFOYWITVVTFOH-UHFFFAOYSA-N 0.000 description 2
- UDJXAOCVFMPIFF-BGYRXZFFSA-N N,N-dimethyl-1-[4-[3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenyl]piperidin-4-amine Chemical compound CN(C1CCN(CC1)C1=CC=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C UDJXAOCVFMPIFF-BGYRXZFFSA-N 0.000 description 2
- XCZMVYRBPMZEGC-KDURUIRLSA-N N,N-dimethyl-3-[4-[3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenoxy]propan-1-amine Chemical compound CN(CCCOC1=CC=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C XCZMVYRBPMZEGC-KDURUIRLSA-N 0.000 description 2
- BHFXJPMWAHYEOS-KDURUIRLSA-N N-ethyl-1-[2-(trifluoromethyl)-4-[3-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenyl]piperidin-4-amine Chemical compound C(C)NC1CCN(CC1)C1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F BHFXJPMWAHYEOS-KDURUIRLSA-N 0.000 description 2
- ICVXSGJUVBXFKH-HDICACEKSA-N N-methyl-1-[2-(trifluoromethyl)-4-[3-[(3S,5R)-3,4,5-trimethylpiperazin-1-yl]-2,4,5,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-12-yl]phenyl]piperidin-4-amine Chemical compound CNC1CCN(CC1)C1=C(C=C(C=C1)C=1C=CC=2N=CC=3N(C=2N=1)C(=NN=3)N1C[C@@H](N([C@@H](C1)C)C)C)C(F)(F)F ICVXSGJUVBXFKH-HDICACEKSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 0 CCN*C(C)C Chemical compound CCN*C(C)C 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710014520.1 | 2017-01-09 | ||
| CN201710014520 | 2017-01-09 | ||
| PCT/CN2018/071851 WO2018127195A1 (zh) | 2017-01-09 | 2018-01-09 | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504139A JP2020504139A (ja) | 2020-02-06 |
| JP2020504139A5 true JP2020504139A5 (enExample) | 2021-02-25 |
| JP7247092B2 JP7247092B2 (ja) | 2023-03-28 |
Family
ID=62789082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537063A Active JP7247092B2 (ja) | 2017-01-09 | 2018-01-09 | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10874670B2 (enExample) |
| EP (1) | EP3567041B1 (enExample) |
| JP (1) | JP7247092B2 (enExample) |
| KR (1) | KR102660196B1 (enExample) |
| CN (1) | CN110167941B (enExample) |
| AU (1) | AU2018206111B2 (enExample) |
| CA (1) | CA3049608A1 (enExample) |
| WO (1) | WO2018127195A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR117951A1 (es) * | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| LT3823971T (lt) | 2018-07-20 | 2022-09-12 | Grünenthal GmbH | Pakeisti triazolo chinoksalino dariniai |
| US20220259211A1 (en) * | 2019-07-10 | 2022-08-18 | Impact Therapeutics (Shanghai), Inc | Substituted pyrazoloquinazolinone compounds and application thereof |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN119080781A (zh) * | 2019-09-12 | 2024-12-06 | 上海瑛派药业有限公司 | 取代的咪唑并喹喔啉化合物及其应用 |
| WO2021218709A1 (zh) | 2020-04-29 | 2021-11-04 | 深圳市韶音科技有限公司 | 声学装置及其磁路组件 |
| KR102458689B1 (ko) * | 2020-07-08 | 2022-10-25 | 원광대학교산학협력단 | 피페리딘 화합물 및 이의 제조 방법 |
| JP2024515964A (ja) * | 2021-04-26 | 2024-04-11 | オハイオ ステート イノベーション ファウンデーション | 脂質ナノ材料及びその使用 |
| CN118103373A (zh) * | 2023-01-18 | 2024-05-28 | 上海德琪医药科技有限公司 | Prmt5抑制化合物和其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| EP2303890A4 (en) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| DE102010025786A1 (de) * | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
| US9181264B2 (en) * | 2010-09-16 | 2015-11-10 | Hutchison Medipharma Limited | Fused heteroaryls and their uses |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| CN103124731B (zh) * | 2010-09-16 | 2016-01-20 | 和记黄埔医药（上海）有限公司 | 稠合的杂芳基化合物及其应用 |
| NO2714752T3 (enExample) | 2014-05-08 | 2018-04-21 |
-
2018
- 2018-01-09 JP JP2019537063A patent/JP7247092B2/ja active Active
- 2018-01-09 EP EP18735878.3A patent/EP3567041B1/en active Active
- 2018-01-09 CA CA3049608A patent/CA3049608A1/en active Pending
- 2018-01-09 CN CN201880006343.5A patent/CN110167941B/zh active Active
- 2018-01-09 KR KR1020197023280A patent/KR102660196B1/ko active Active
- 2018-01-09 US US16/476,762 patent/US10874670B2/en active Active
- 2018-01-09 WO PCT/CN2018/071851 patent/WO2018127195A1/zh not_active Ceased
- 2018-01-09 AU AU2018206111A patent/AU2018206111B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7337174B2 (ja) | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 | |
| JP7696443B2 (ja) | Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
| EP3288558B1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| WO2021149817A1 (en) | Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers | |
| JP7671425B2 (ja) | Ｃｄｋ阻害剤 | |
| ES2816382T3 (es) | Compuestos de alquinilbenceno heterocíclicos, y composiciones médicas y usos de los mismos | |
| CN111201223A (zh) | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 | |
| AU2019316858B2 (en) | Smad3 inhibitors | |
| US20210000825A1 (en) | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | |
| WO2021074251A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives and their use in the treatment of cancer | |
| JP2020504139A (ja) | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 | |
| CA3115068A1 (en) | Method for preparing and delivering bisantrene formulations | |
| JP2024513538A5 (enExample) | ||
| WO2023147015A1 (en) | Substituted heterocyclic csnk1 inhibitors | |
| WO2025171225A1 (en) | Compositions and methods for inducing ferroptosis | |
| WO2026011344A1 (en) | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway | |
| HK40067698A (en) | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof | |
| TW202304925A (zh) | （呋喃并嘧啶—４—基）哌𠯤化合物及其用途 |